From: The role of immune checkpoint inhibition in the treatment of ovarian cancer
Phase | Trial number | Trial | Disease status | Immunotherapy agent(s) | Concurrent therapy |
---|---|---|---|---|---|
3 | NCT02580058 | A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | recurrent platinum resistant | Avelumab | Liposomal Doxorubicin |
3 | NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | primary | Avelumab | Carboplatin Paclitaxel |
3 | ENGOT-ov29-GCIG | A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab | recurrent platinum sensitive | Atezolizumab | Carboplatin-based chemotherapy Bevacizumab |
2 | NCT02440425 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | recurrent platinum resistant | Pembrolizumab | Dose Dense Paclitaxel |
2 | NCT02498600 | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recurrent platinum sensitive/resistant | Nivolumab +/- Ipilimumab | Â |
2 | NCT02520154 | Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer | primary | Pembrolizumab | Carboplatin Paclitaxel |
2 | NCT02659384 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | recurrent platinum resistant | Atezolizumab | Bevacizumab Acetylsalicylic Acid |
2 | NCT02674061 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | recurrent platinum sensitive/resistant | Pembrolizumab | Â |
2 | NCT02764333 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | recurrent platinum resistant | Durvalumab | TPIV200/huFR-1 (anti-folate receptor vaccine) |
2 | NCT02766582 | Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | suboptimally cytoreduced primary | Pembrolizumab | Carboplatin Paclitaxel |
1/2 | NCT02431559 | A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated | recurrent platinum resistant | Durvalumab | Motolimod Pegylated Liposomal Doxorubicin |
1/2 | NCT02484404 | Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer | recurrent platinum sensitive/resistant | Durvalumab | Olaparib or Cediranib |
1/2 | NCT02485990 | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | recurrent or persistent | Tremelimumab | Olaparib |
1/2 | NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | BRCA-deficient recurrent platinum sensitive/resistant | Tremelimumab | Olaparib |
1/2 | NCT02657889 | Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162) | recurrent platinum resistant | Pembrolizumab | Niraparib |
1/2 | NCT02726997 | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer | primary | Durvalumab | Carboplatin Paclitaxel |
1 | NCT02737787 | A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | ≥2nd remission | Nivolumab | WT1 vaccine |
0 | NCT02728830 | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | primary | Pembrolizumab | Â |